Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Nuffield Department of Primary Care Health Sciences at the University of Oxford and the Royal College of General Practitioners (RCGP) have joined forces with clinical system supplier EMIS Health to urgently recruit as many GP practices as possible for COVID-19 research.

Today, the Oxford RCGP’s Research and Surveillance Centre (RSC) has written to nearly 4,000 GP practices in England using EMIS Health systems asking them to contribute patient data to help them develop a deeper understanding of the COVID-19 pandemic in general practice.

The data – shared under strict governance guidelines – will enable researchers to understand the spread of COVID-19, including tracking when it peaks and helping to inform government strategy around measures such as social distancing and lockdown. Practices are also being asked to support public health surveillance by supplying samples from symptomatic patients and providing extra blood samples from asymptomatic patients having routine blood tests. Some practices are also being asked to take part in rapid clinical trials of selected medicines to reduce the duration and severity of the virus. The first trial will need up to 3,000 patients. As many practices as possible are needed to support the work.

Professor Richard Hobbs, Head of Department of Primary Care Health Sciences said, 'This has been an extraordinary collaborative effort to compress many months of work into a few days. We are finalising the first national COVID-19 trial outside of hospital, led by Professor Chris Butler; significantly extending the only national surveillance of COVID-19 outside of hospitals; and considering efficient COVID-19 information feedback to practices.'

Read the full story on the Department of Primary Care Health Sciences website

This story is also featured on the University of Oxford website

Similar stories

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.